Angioimmunoblastic T-Cell Lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Angioimmunoblastic T-cell lymphoma (AITL) is a complex follicular T-helper cell neoplasm.
• It typically affects elderly patients and is associated with aggressive behavior.
• Current anthracycline-based treatments yield poor outcomes.

Purpose of the Study:

• To review the pathogenetic events, clinical behavior, and treatment outcomes of AITL.
• To highlight the need for novel therapeutic strategies for relapsed and refractory AITL.
• To propose innovative induction strategies for improved patient survival.

Main Methods:

• Review of recent literature on AITL pathogenesis and treatment.
• Analysis of outcomes with current and emerging therapies.
• Evaluation of novel agents and combination strategies.

Main Results:

• New mutations are identified, aiding in understanding AITL pathogenesis.
• Autologous transplantation in first remission is recommended when feasible.
• Newly approved agents show limited response duration in pretreated patients.

Conclusions:

• AITL requires urgent development of new treatment approaches.
• Innovative induction strategies, such as CHOP plus a biologic agent, are needed.
• Enhanced response quality and prolonged survival are key goals for future AITL therapies.